Medical Research Center

Fu, Li (Professor)
Medical Research Center
Pharmacology
Professor (Director of Tumor Microenvironment Laboratory)
Intro:

                                                         BIOGRAPHICAL SKETCH

NAME: Fu, Li

POSITION TITLE: Professor, Director of Tumor Microenvironment Laboratory

EDUCATION/TRAINING


INSTITUTION AND LOCATION            DEGREE        COMPLETION DATE     FIELD OF STUDY

                                                                                                MM/YYYY

 

Wuhan University School of Medicine     M.B.B.S                      06/1998               Medicine

Wuhan, China

 

National University of Singapore             M.Sc.                          04/2001               Endocrinology

Singapore  

 

The University of Hong Kong                   Ph.D.                         11/2007                Cancer Genetics

Hong Kong, China

 

The University of Hong Kong                  Postdoctoral               09/2010                Cancer Biology

             Hong Kong, China

 

A. Personal Statement

 

My research goal is to understand the mechanisms of initiation and progression of gastrointestinal (GI) cancers and identify new therapeutic targets for cancer treatment.  I have formulated three research directions:

1. Molecular characterization of the tumor and its microenvironment;                                                                              

2. Cancer-stroma targeting therapeutic development;    

3. Prognostic and predictive biomarker discovery and development.

 

The research in my laboratory has been continuously supported by the National Natural Science Foundation in China (NSFC), General Research Fund (GRF) of Hong Kong, and grants from the Shenzhen Science and Technology Innovation Department since 2014.  I have published 60 papers in the cancer research field in various peer-reviewed international journals (H-Index 21). I have obtained two China patents and have been awarded the Overseas High-level Talents and Pengcheng Scholar Distinguish Professorship by the Shenzhen Government. I am currently mentoring two postdoctoral fellows and one PhD and three MSc candidates.

 

B. Positions and Honors

             Positions and Employment    

04/01-09/04      Research Fellow, Tumor Virology/Cancer Epigenetics Laboratory, Johns Hopkins Singapore, Singapore

09/10-09/13      Research Assistant Professor, Department of Clinical Oncology, University of Hong Kong, Hong Kong, China

09/13-09/14      Principle Investigator, State Key Laboratory of Digestive Diseases, Chinese University of Hong Kong, Hong Kong, China

09/14-present   Professor, Department of Pharmacology and Cancer Research Center, Shenzhen University School of Medicine, Shenzhen, China

 

C. Representative publications (*: corresponding/co-corresponding author)

A full list of my publications (in a total of 60) is enclosed at the end of this document.

 

1.      Molecular characterization of tumor microenvironment

Our group has been studying the esophageal cancer microenvironment since 2008. Using cDNA microarray analyses, we identified the FGFR2 gene as a specific biomarker of cancer-associated fibroblasts (CAFs) in esophageal squamous cell carcinoma (ESCC; Clin Cancer Res, 2009). We further revealed that FGFR2(+)CAFs-secreted WNT2 supports the malignant progression of ESCC cells in a non-cell-autonomous manner. We also provided the first evidence that WNT2 is highly and specifically expressed in CAFs and may serve as a prognostic marker for patients with ESCC (Gut, 2011). Our current efforts are focusing on studying tumor–stroma interactions and developing molecular prognostic and therapeutic strategies for ESCC.

 

1)     Zhang C^, Fu L^, Fu J, Hu L, Yang H, Rong TH, Li Y, Liu H, Fu SB, Zeng YX, Guan XY. Fibroblast growth factor receptor 2-positive fibroblasts provide a suitable microenvironment for tumor development and progression in esophageal carcinoma. Clin Cancer Res 2009;15(12):4017-27.

2)     Fu L, Zhang C, Zhang LY, Dong SS, Lu LH, Chen J, Dai YD, Li Y, Kwong DL, Guan XY. Wnt2 secreted by tumor fibroblasts promotes tumor progression in oesophageal cancer via the activation of Wnt/β-catenin signaling pathway. Gut 2011;60(12):1635-43.

 

2.      Identification and characterization of novel tumor markers

ESCC and Hepatocellular Carcinoma (HCC) are common yet fatal malignances in the Chinese population. Our previous studies have utilized genomic/proteomic approaches to identify novel tumor suppressor genes and oncogenes that can influence ESCC and HCC development. We have functionally characterized a panel of novel tumor markers and explored the mechanisms underlying the pathogenesis of both types of cancers.

 

1)     Fu L, Qin YR, Xie D, Hu L, Kwong D,  Srivastava G, Tsao SW, Guan XY.  Characterization of a novel tumor suppressor gene phospholipase C-δ1 at frequently deleted region 3p22 in esophageal squamous cell carcinoma. Cancer Res 2007;67(22):10720-6.

2)     Fu L, Dong SS, Xie YW, Tai LS, Chen L, Kong KL, Man K, Xie D, Li Y, Cheng Y, Tao Q, Guan XY. Downregulation of tyrosine aminotransferase at a frequently deleted region 16q22 contributes to the pathogenesis of hepatocellular carcinoma. Hepatology2010;51(5):1624-34.

3)     Qin YR, Tang H, Xie FJ, Liu HB, Zhu YH, Chen L, Li Y, Kwong DL, Fu L*, Guan XY. Characterization of tumor-suppressive function of SOX6 in human esophageal squamous cell carcinoma.Clin Cancer Res 2011;17(1):1-10.

4)     Zhang LY, Wu JL, Qiu HB, Dong SS, Zhu YH, Lee VH, Qin YR, Li Y, Chen J, Liu HB, Bi J, Ma S, Guan XY, Fu L*. PSCA acts as a tumor suppressor by facilitating the nuclear translocation of RB1CC1 in esophageal squamous cell carcinoma.Carcinogenesis 2016;37(3):320-32.

5)     Cao TT, Lin SH, Fu L*, Tang Z, Che CM, Zhang LY, Ming XY, Liu TF, Tang XM, Tan BB, Xiang D, Li F, Chan OY, Xie D, Cai Z, Guan XY. Eukaryotic translation initiation factor 5A2 promotes metabolic reprogramming in hepatocellular carcinoma cells.Carcinogenesis 2017 38(1):94-104.

6)     Fu L*, Qin YR, Ming XY, Zuo X, Diao YW, Zhang LY, Ai J, Liu BL, Huang TX, Cao TT, Tan BB, Xiang D, Zeng CM, Gong J, Zhang Q, Dong SS, Chen J, Liu H, Wu JL, Qi RZ, Xie D, Wang LD, Guan XY. RNA editing of SLC22A3 drives early tumor invasion and metastasis in familial esophageal cancer. PNAS 2017;114(23):E4631-40.

 

D. Research Support

Ongoing Research Support

 

1.    NSFC (China) general project (81772957)                          01/01/2018 to 12/31/2021

        Li FU, PI                                                                                    ¥500,000

Significance of MAPK10-mediated antioxidant defense in hepatocarcinogenesis.

 

2.    Shenzhen STIC Peacock project (KQTD20140630100658078) 02/01/2015 to 01/01/2020

Li FU, Co-PI                                                                                      ¥15,000,000

Development of  immunotherapy approach targeting cancer stem cell

 

3.    CRF (Hong Kong) project (C7038-14G)                              04/01/2015 to 06/31/2018

Li FU, Co-PI                                                                               HK$3,000,000

Investigation of effects and molecular mechanisms of FGFR2-positive cancer-associate fibroblasts on tumor microenvironment in esophageal squamous cell carcinoma.

 

            Completed Research Support

1.    NSFC (China) general project (81372583)                          01/01/2014 to 12/31/2017

Li FU, PI                                                                                    ¥700,000

Tumor fibroblasts secreted WNT2 as a novel therapeutic target in esophageal squamous cell carcinoma.

 

2.    GRF (Hong Kong) general project (CUHK766613)              01/01/2014 to 12/31/2017

            Li FU, PI                                                                                     HK$736,128

Characterization of WNT2 in the esophageal cancer microenvironment: prognostic and therapeutic implications.

 

3.    Shenzhen STIC key project (CXZZ20150430092951135)  08/15/2015-12/31/2017

            Li FU, PI                                                                                     ¥1,500,000

Pre-clinical investigation of novel anti-tumor vaccines by targeting breast cancer stem cell.

 

 

E. Peer-reviewed publications (*: corresponding author)

 

1.      Liu DB, Wong CC, Fu L, Chen H, Zhao L, Li C, Zhou Y, Zhang Y, Xu uW, Wu B, Yang Y, Chen G, Lai P, Wong N, Sung JJ, Yu J. Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a direct pharmaceutical target. Sci Tran Med, 2018, In Press.

 

2.      Chen X, Loo JX, Shi X, Xiong W, Guo Y, Ke H, Yang M, Jiang Y, Xia S, Zhao M, Zhong S, He C, Fu L, Li F. E6 protein expressed by high-risk HPV activates super-enhancers of the EGFR and c-MET oncogenes by destabilizing the histone demethylase KDM5C. Cancer Res 2018 Jan 16.

 

3.      He JS, Xie N, Yang JB, Guan H, Chen WC, Zou C, Ouyang YW, Mao YS, Luo XY, Pan Y, Fu L*. BCSG1 siRNA delivered by lentiviral vector suppressed proliferation and migration of MDA-MB-231 cells. Int J Mol Med 2018 Mar;41(3):1659-1664.

4.       Fu L*, Qin YR, Ming XY, Zuo X, Diao YW, Zhang LY, Ai J, Liu BL, Huang TX, Cao TT, Tan BB, Xiang D, Zeng CM, Gong J, Zhang Q, Dong SS, Chen J, Liu H, Wu JL, Qi RZ, Xie D, Wang LD, Guan XY. RNA editing of SLC22A3 drives early tumor invasion and metastasis in familial esophageal cancer. PNAS 2017;114(23):E4631-40.

5.      He JS, Guan H, Yang J, Zheng D, Fu L, Chen WC, Luo XY, Mao YS, OuYang YW, Pan Y, Zou C. siRNA-mediated suppression of collagen type iv alpha 2 (COL4A2) mRNA inhibits triple-negative breast cancer cell proliferation and migration. Oncotarget 2017 Jan 10;8(2):2585-2593.

6.      Li G, Su Q, Liu H, Wang D, Zhang W, Lu Z, Chen Y, Huang X, Li W, Zhang C, He Y, Fu L, Bi J. Frizzled7 promotes epithelial-to-mesenchymal transition and stemness via activating canonical Wnt/β-catenin pathway in gastric cancer. Int J Biol Sci 2018; 14(3): 280-293.

7.      Cao TT, Xiang D, Liu BH, Huang TX, Tan BB, Zeng CM, Wang Z, Ming XY, Zhang LY, Jing G, Li F, Wu JL, Guan XY, Lu D, Fu L*. FZD7 is a novel prognostic marker and promotes tumor metastasis via WNT and EMT signaling pathways in esophageal squamous cell carcinoma. Oncotarget 2017;8(39):65957-65968.

8.      Cao TT, Lin SH, Fu L*, Tang Z, Che CM, Zhang LY, Ming XY, Liu TF, Tang XM, Tan BB, Xiang D, Li F, Chan OY, Xie D, Cai Z, Guan XY. Eukaryotic translation initiation factor 5A2 promotes metabolic reprogramming in hepatocellular carcinoma cells. Carcinogenesis 2017 38(1):94-104.

9.      Zou C, Zhao P, Xiao Z, Han X, Fu F, Fu L*. γδT cells in cancer immunotherapy. Oncotarget 2017;8(5):8900-9.

10.   Xu W, Zhang X, Wu JL, Fu L, Liu K, Liu D, Chen GG, Lai PB, Wong N, Yu J. O-GlcNAc transferase promotes fatty liver-associated liver cancer through inducing palmitic acid and activating endoplasmic reticulum stress. J Hepatol 2017;67(2):310-20.

11.   Tian B, Chen X, Zhang H, Li X, Wang J, Han W, Zhang LY, Fu L, Li Y, Nie C, Zhao Y, Tan X, Wang H, Guan XY, Hong A. Urokinase plasminogen activator secreted by cancer-associated fibroblasts induces tumor progression via PI3K/AKT and ERK signaling in esophageal squamous cell carcinoma. Oncotarget 2017;8(26):42300-13.

12.   Ming XY, Fu L, Zhang LY, Qin YR, Cao TT, Chan KW, Ma S, Xie D, Guan XY. Integrin α7 is a functional cancer stem cell surface marker in oesophageal squamous cell carcinoma. Nature Communications 2016;7:13568. 

13.   Zhang LY, Wu JL, Qiu HB, Dong SS, Zhu YH, Lee VH, Qin YR, Li Y, Chen J, Liu HB, Bi J, Ma S, Guan XY, Fu L*. PSCA acts as a tumor suppressor by facilitating the nuclear translocation of RB1CC1 in esophageal squamous cell carcinoma. Carcinogenesis 2016;37(3):320-32.

14.   Lin SH, Liu T, Ming X, Tang Z, Fu L, Schmitt-Kopplin P, Kanawati B, Guan XY, Cai Z. Regulatory role of hexosamine biosynthetic pathway on hepatic cancer stem cell marker CD133 under low glucose conditions. Sci Rep 2016;6:21184.

15.   Tang Z, Cao TT, Lin SH, Fu L, Li SF, Guan XY, Cai Z. Characterization of Oncogene-induced metabolic alterations in hepatic cells by using ultrahigh performance liquid chromatography-tandem mass spectrometry. Talanta 2016;152:119-26.

16.   Diao Y, Wang X, Wan Y, Zhong J, Gao D, Liu Y, Gao N, Li W, Liu B, Huang X, Jin Z, Wang Z, Fu L, Chen S, Jin G. Antitumor activity of a novel small molecule TLR7 agonist via immune response induction and tumor microenvironment modulation. Oncol Rep 2016;35(2):793-800.

17.   Jiang L, Kwong DL, Li Y, Liu M, Yuan YF, Li Y, Fu L, Guan XY. HBP21, a chaperone of heat shock protein 70, functions as a tumor suppressor in hepatocellular carcinoma. Carcinogenesis 2015;36(10):1111-20.

18.   Chen J, Kwong DL, Cao T, Hu Q, Zhang L, Ming X, Chen J, Fu L*, Guan XY. Esophageal squamous cell carcinoma (ESCC): advance in genomics and molecular genetics. Dis Esophagus 2015;28(1):84-9.

19.   Liu M, Li Y, Chen L, Chan TH, Song YY, Fu L, Zeng TT, Dai YD, Zhu YH, Li Y, Chen J, Yuan YF, Guan XY. Allele-specific imbalance of oxidative stress-induced growth inhibitor 1 associates with progression of hepatocellular carcinoma. Gastroenterology 2014;146(4):1084-96.

20.   Lu P, Qiao J, He W, Wang J, Jia Y, Sun Y, Tang S, Fu L, Qin Y. Genome-wide gene expression profile analyses identify CTTN as a potential prognostic marker in esophageal cancer. PLoS One 2014;9(2):e88918.

21.   Li Y,  Fu L,  Li JB, Qin YR,  Zeng TT, Zhou J, Zeng ZL, Chen J, Cao TT, Ban XJ, Qian C, Cai Z, Xie D, Huang P, Guan XY. Increased Expression of EIF5A2, via hypoxia or gene amplification, contributes to metastasis and angiogenesis of esophageal squamous cell carcinoma. Gastroenterology 2014;146(7):1701-1713.

22.   Li JC, Li Y, Ai JY, Chen K, Zhu YH, Fu L, Qin YR, Wang LJ, Guan XY. Podoplanin‑positive cancer cells at the edge of esophageal squamous cell carcinomas are involved in invasion. Mol Med Rep 2014;10(3):1513-8.

23.   Jiang L, Yang YD, Fu L, Xu W, Liu D, Liang Q, Zhang X, Xu L, Guan XY, Wu B, Sung JJ, Yu J. CLDN3 inhibits cancer aggressiveness via Wnt-EMT signaling and is a potential prognostic biomarker for hepatocellular carcinoma. Oncotarget 2014;5(17):7663-76.

24.   Zhang LY, Lee VH, Wong-Go AM, Kwong DL, Zhu YH, Dong SS, Kong KL, Chen J, Tsao SW, Guan XY, Fu L*. MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN. Carcinogenesis 2013;34(2):454-63.

25.   Liu HB, Qin YR, Bi J, Guo AL, Fu L*, Guan XY. Overexpression of matrix metalloproteinase 10 is associated with poor survival in patients with early stage of esophageal squamous cell carcinoma. Dis Esophagus 2012;25(7):656-63.

26.   Chen L, Li Y, Lin CH, Chan TH, Chow RK, Song Y, Liu M, Yuan YF, Fu L, Kong KL, Qi L, Li Y, Zhang N, Tong AH, Kwong DL, Man K, Lo CM, Lok S, Tenen DG, Guan XY. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat Med 2013;19(2):209-16.

27.   Zhu YH, Fu L, Chen L, Qin YR, Liu H, Xie FJ, Zeng TT, Dong SS, Li J, Li Y, Dai Y, Xie D, Guan XY. Downregulation of the novel tumor suppressor DIRAS1 predicts poor prognosis in esophageal squamous cell carcinoma. Cancer Res 2013;73(7):2298-309.

28.   Tang KH, Dai Y, Tong M, Chan YP, Fu L, Qin YR, Tsao SW, Tong DK, Law S, Chan KW, Ma S, Guan XY. A CD90(+) tumor-initiating cell population with an aggressive signature and metastatic capacity in esophageal cancer. Cancer Res 2013;73(7):2322-32.

29.   Li J, Li XD, Li Y, Yang H, Wang LJ, Qin YR, Liu H, Fu L, Guan XY. Cell-specific detection of miR-375 downregulation for predicting the prognosis of esophageal squamous cell carcinoma by miRNA in situ hybridization. PLoS One 2013;8(1):e53582.

30.   Li Y, Zhu CL, Nie CJ, Li JC, Zeng TT, Zhou J, Chen J, Chen K, Fu L, Liu H, Qin Y, Guan XY. Investigation of tumor suppressing function of CACNA2D3 in esophageal squamous cell carcinoma. PLoS One 2013;8(4):e60027.

31.   Chen K, Li Y, Dai YD, Qin YR, Zhu YH, Zeng TT, Fu L, Guan XY. Characterization of tumor suppressive function of cornulin in esophageal squamous cell carcinoma. PLoS One 2013;8(7):e68838. 

32.   Ma S, Bao JYJ, Chan YP, Kwan PS, Fu L, Zhang N, Tong AHY, Tang KH, Tong CM, Qin YR, Tsao SW, Chan KW, Lok S, Guan XY. Identification of PTK6, via RNA sequencing analysis, as a suppressor of esophageal squamous cell carcinoma. Gastroenterology 2012;143(3):675-86.

33.   Tong M, Chan KW, Bao JY, Wong KY, Kwan PS, Tang KH, Fu L, Qin YR, Lok S, Guan XY, Ma S. Rab25 is a tumor suppressor gene with antiangiogenic and anti-invasive activities in esophageal squamous cell carcinoma. Cancer Res 2012;72(22):6024-35.

34.   Xie FJ, Zhao P, Kou JY, Hong W, Fu L, Hu L, Hong D, Su D, Gao Y, Zhang YP. The T393C polymorphism of GNAS1 as a predictor for chemotherapy sensitivity and survival in advanced non-small-cell lung cancer patients treated with gemcitabine plus platinum. Cancer Chemother Pharmacol 2012;69(6):1443-8.

35.   Chen J, Fu L, Zhang LY, Kwong DL, Yan L, Guan XY. Tumor suppressor genes on frequently deleted chromosome 3p in nasopharyngeal carcinoma. Chin J Cancer 2012;31(5):215-22.

36.   Chen J, Zhu CL, Chen L, Dong SS, Zhang LY, Tian J, Qi CB, Wong-Go AM,  Kong KL, Li  Y, Liu M, Kwong DL, Fu L*, Guan XY. RBMS3 at 3p24 inhibits nasopharyngeal carcinoma development via inhibiting cell proliferation, angiogenesis, and inducing apoptosis. PLoS One 2012;7(9):e44636.

37.   Qin YR, Tang H, Xie FJ, Liu HB, Zhu YH, Chen L, Li Y, Kwong DL, Fu L*, Guan XY. Characterization of tumor-suppressive function of SOX6 in human esophageal squamous cell carcinoma. Clin Cancer Res 2011;17(1):1-10.

38.   Xie FJ, Liu HB, Zhu YH, Zeng TT, Dai YD, Chen L, Nie CJ, Tang H, Li Y, Fu L*, Guan XY. Overexpression of GPR39 contributes to malignant development of human esophageal squamous cell carcinoma. BMC Cancer 2011;11:86.

39.   Fu L, Zhang C, Zhang LY, Dong SS, Lu LH, Chen J, Dai YD, Li Y, Kwong DL, Guan XY. Wnt2 secreted by tumor fibroblasts promotes tumor progression in oesophageal cancer via the activation of Wnt/β-catenin signaling pathway. Gut 2011;60(12):1635-43.

40.   Li Y^,Fu L^,Wong AM,Fan YH,Li MX,Bei JX,Jia WH,Zeng YX,Chan D,Cheung KM,Sham P,Chua D,Guan XY,Song YQ. Identification of genes with allelic imbalance on 6p associated with nasopharyngeal carcinoma in southern Chinese. PLoS One 2011;6(1):e14562.

41.   Li Y, Chen L, Nie CJ, Zeng TT, Liu H, Mao X, Qin Y, Zhu YH, Fu L, Guan XY. Downregulation of RBMS3 is associated with poor prognosis in esophageal squamous cell carcinoma. Cancer Res 2011;71(19):6106-15.

42.   Fu L, Dong SS, Xie YW, Tai LS, Chen L, Kong KL, Man K, Xie D, Li Y, Cheng Y, Tao Q, Guan XY. Down-regulation of tyrosine aminotransferase at a frequently deleted region 16q22 contributes to the pathogenesis of hepatocellular carcinoma. Hepatology 2010;51(5):1624-34.

43.   Tang DJ, Dong SS, Ma NF, Xie D, Chen L, Fu L, Lau SH, Li Y, Li Y, Guan XY. Overexpression of EIF5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma. Hepatology 2010;51(4):1255-63.

44.   Li Y, Nie CJ, Hu L, Qin YR, Liu HB, Zeng TT, Chen LL, Fu L, Deng W, Chen SP, Jia WH, Xie D, Guan  XY. Characterization of a novel mechanism of genomic instability involving the SEI1/SET/NM23H1 pathway in esophageal cancers. Cancer Res 2010;70(14):5695-705.

45.   Kong KL, Kwong DL, Fu L, Liu HB, Li Y, Zhu YH, Bi J, Qin YR, Guan XY. Characterization of a candidate tumor suppressor gene uroplakin 1A in esophageal squamous cell carcinoma. Cancer Res 2010;70(21):8832-41.

46.   Fu L, Gao Z, Zhang X, Tang YH, Goh HK, Geng H, Shimizu N, Tsuchiyama J, Srivastava G, Tao Q. Frequent concomitant epigenetic silencing of the stress-responsive tumor suppressor gene CADM1, and its interacting partner DAL-1 in nasal NK/T-cell lymphoma. Int J Cancer 2009;124(7):1572-8.

47.   Zhang C^, Fu L^, Fu J, Hu L, Yang H, Rong TH, Li Y, Liu H, Fu SB, Zeng YX, Guan XY. Fibroblast growth factor receptor 2-positive fibroblasts provide a suitable microenvironment for tumor development and progression in esophageal carcinoma. Clin Cancer Res 2009;15(12):4017-27.

48.   Chen L, Hu L, Chan TH, Tsao GS, Xie D, Huo KK, Fu L, Ma S, Zheng BJ, Guan XY. Chromodomain helicase/adenosine triphosphatase DNA binding protein 1-like (CHD1l) gene suppresses the nucleus-to-mitochondria translocation of nur77 to sustain hepatocellular carcinoma cell survival. Hepatology 2009;50(1):122-9.

49.   Zhu C, Qin YR, Xie D, Chua DT, Fung JM, Chen L, Fu L, Hu L, Guan XY. Characterization of tumor suppressive function of P300/CBP-associated factor at frequently deleted region 3p24 in esophageal squamous cell carcinoma. Oncogene 2009;28(31):2821-8.

50.    Hu XT, Zhang FB, Fan YC, Shu XS, Wong AH, Zhou W, Shi QL, Tang HM, Fu L, Guan XY, Rha SY, Tao Q, He C. Phospholipase C delta 1 is a novel 3p22.3 tumor suppressor involved in cytoskeleton organization, with its epigenetic silencing correlated with high-stage gastric cancer. Oncogene 2009;28(26):2466-75.

51.   Chow BHY, Chua DTT, Sham JST, Zhang MY, Chow LWC, Bi J, Ma NF, Xie D, Loo WTY, Fung JMW, Fu L, Guan XY. Increased expression of annexin I is associated with drug-resistance in nasopharyngeal carcinoma and other solid tumors. Proteomics Clin Appl 2009;3(6):654-62.

52.   Qin YR^, Fu L^, Sham PC, Kwong DLW, Zhu CL, Chu KKW, Li Y, Guan XY. Single-nucleotide polymorphism-mass array reveals commonly deleted regions at 3p22 and 3p14.2 associate with poor clinical outcome in esophageal squamous cell carcinoma. Int J Cancer 2008;123(4): 826-30.

53.   Ma NF, Hu L, Fung JM, Xie D, Zheng BJ, Chen LL, Tang DJ, Fu L, Wu ZG, Chen MH, Fang Y, Guan XY. Isolation and characterization of a novel oncogene ALC1 within a commonly amplified region at 1q21 in hepatocellular carcinoma. Hepatology 2008;47(2):503-10.

54.   Ma NF, Lau SH, Hu L, Xie D, Wu J, Yang J, Wang Y, Wu MC, Fung J, Bai X, Tzang CH, Fu L, Yang M, Sun YA, Guan XY. COOH-terminal truncated HBV X protein plays key role in hepatocarcinogenesis. Clin Cancer Res 2008;14(16):5061-8.

55.   Fu L, Qin YR, Xie D, Hu L, Kwong D,  Srivastava G, Tsao SW, Guan XY. Characterization of a novel tumor suppressor gene phospholipase C-δ1 at frequently deleted region 3p22 in esophageal squamous cell carcinoma. Cancer Res 2007;67(22):10720-6.

56.   Fu L, Qin YR, Xie D, Chow B, Ngai SM, Kwong D, Li Y, Guan XY. Identification of alpha-actinin 4 and 67 kDa laminin receptor as stage-specific markers in esophageal cancer via proteomic approaches. Cancer 2007;110(12):2672-81.

57.    Tai AL, Mak W, Ng PK, Chua DT, Ng MY, Fu L, Chu KK, Fang Y, Song YQ, Chen M, Zhang M, Sham PC, Guan XY. High-throughput loss-of-heterozygosity study of chromosome 3p in lung cancer using single-nucleotide polymorphism markers. Cancer Res 2006;66(8):4133-8.

58.   Wong ML, Tao Q, Fu L, Wong KY, Qiu GH, Law FB, Tin PC, Cheung WL, Lee PY, Tang JC, Tsao GS, Lam KY, Law S, Wong J, and Srivastava G. Aberrant promoter hypermethylation and silencing of the critical 3p21 tumour suppressor gene, RASSF1A, in Chinese oesophageal squamous cell carcinoma. Int J Oncol 2006;28(3):767-73.

59.   Murray PG, Qiu GH, Fu L, Waites ER, Srivastava G, Agathanggelou A, Latif F, Grundy RG, Mann JR, Starzynski J, Crocker J, Parkes SE, Ambinder RF, Young LS, Tao Q. Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma. Oncogene 2004;23(6):1326-31.

60.   Tao Q, Huang H, Geiman TM, Lim CY, Fu L, Qiu GH, Robertson KD. Defective de novo methylation of viral and cellular DNA sequences in ICF syndrome cells. Hum Mol Genet 2002;11(18):1-12.

 

 

   

Tel: 86-755-86671992

 

Email: gracelfu@szu.edu.cn